Tuesday, 13 October 2026 Updated 16 min ago
The News Engine
Latest
Business United States

Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim

Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim.

CNBC reports: Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim.

This business story centres on the United States. Names and organisations mentioned in the coverage include Martin Shkreli, FTC and Daraprim.

Why it matters

Moves like this are watched by investors, employers and consumers because of their potential effect on markets and the wider economy.

Key details

Location
United States · Americas
Reported by
CNBC
First reported
Key names
Martin Shkreli, FTC, Daraprim
Section
Business

Sources

This is an independent summary. Read the full, original reporting from the publisher:

Read the full story at CNBC

Spotted an error? Request a correction · How this summary was produced

Related Stories